ERBB2 and neoplasm: In parallel, Her-2/neu activation status of tumour specimens was assessed by immunohistochemistry using a Her-2/neu phosphorylation state specific antibody (PN2A) and correlated with the patients’ ECD levels and clinical course of disease.